BRIEF—Tremfya approved for psoriasis and psoriatic arthritis in Japan, Brazil and Australia

Germany-based MorphoSys AG (FSE: MOR) says that its licensee Janssen Pharmaceutical KK, a unit of Johnson & Johnson (NYSE: JNJ) has received approval from Japan's Ministry of Health, Labor and Welfare (MHLW) for Tremfya (guselkumab) for the treatment of three forms of psoriasis (plaque, pustular, and erythrodermic) and psoriatic arthritis in patients with moderate-to-severe disease for whom other existing treatments have failed.

In addition, Janssen reported that Tremfya has been approved for the treatment of adults living with moderate to severe plaque psoriasis in Brazil and Australia.

Tremfya is a fully human anti-interleukin (IL)-23 monoclonal antibody developed by Janssen and was generated utilizing MorphoSys' proprietary HuCAL antibody library technology. MorphoSys is eligible to receive royalties on net sales of Tremfya in these markets.